MovDisordV3, Main, Exploration, bibRecord, 004C50

Riluzole therapy in Huntington's disease (HD)

Identifieur interne : 004C50 ( Main/Exploration ); précédent : 004C49; suivant : 004C51

Riluzole therapy in Huntington's disease (HD)

Auteurs : H. Diana Rosas [États-Unis] ; Walter J. Koroshetz [États-Unis] ; Bruce G. Jenkins [États-Unis] ; Y. Iris Chen ; Douglas L. Hayden [États-Unis] ; M. Flint Beal [États-Unis] ; Merit E. Cudkowicz [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1999-03.

RBID : ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0

Descripteurs français

Pascal (Inist)
- Antagoniste, Benzothiazole, Chimiothérapie, Chorée Huntington, Encéphale, Homme, Psychotrope, Riluzole, Récepteur glutamate, Spectrométrie RMN, Traitement.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adult, Antagonist, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Benzothiazole, Brain (vertebrata), Chemotherapy, Chorea, Chorea (drug therapy), Energy metabolism, Excitatory Amino Acid Antagonists (adverse effects), Excitatory Amino Acid Antagonists (therapeutic use), Female, Glutamate receptor, Human, Humans, Huntington Disease (drug therapy), Huntington Disease (metabolism), Huntington disease, Huntington's disease, Lactate, Lactic Acid (metabolism), Magnetic Resonance Spectroscopy, Magnetic resonance spectroscopy, Male, Middle Aged, NMR spectrometry, Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Occipital Lobe (drug effects), Occipital Lobe (metabolism), Pilot Projects, Psychotropic, Riluzole, Riluzole (adverse effects), Riluzole (therapeutic use), Severity of Illness Index, Single-Blind Method, Treatment, Treatment Outcome.
MESH :
- chemical , adverse effects : Excitatory Amino Acid Antagonists, Neuroprotective Agents, Riluzole.
- drug effects : Basal Ganglia, Occipital Lobe.
- drug therapy : Chorea, Huntington Disease.
- metabolism : Basal Ganglia, Huntington Disease, Lactic Acid, Occipital Lobe.
- chemical , therapeutic use : Excitatory Amino Acid Antagonists, Neuroprotective Agents, Riluzole.
- Adult, Female, Humans, Magnetic Resonance Spectroscopy, Male, Middle Aged, Pilot Projects, Severity of Illness Index, Single-Blind Method, Treatment Outcome.

Abstract

We conducted a 6‐week open‐label trial of riluzole (50 mg twice a day) in eight subjects with Huntington's disease. Subjects were evaluated before riluzole treatment, on treatment, and off treatment with the chorea, dystonia, and total functional capacity (TFC) scores from the Unified Huntington's Disease Rating Scale and magnetic resonance spectroscopy measurements of occipital cortex and basal ganglia lactate levels. Adverse events and safety blood and urine tests were assessed throughout the study. All subjects completed the study and riluzole was well tolerated. The age was 45 ± 10.2 years (mean ± standard deviation) and the disease duration was 6.1 ± 4.1 years. The chorea rating score improved by 35% on treatment (p = 0.013) and worsened after discontinuation of treatment (p = 0.026). There were no significant treatment effects on the dystonia or TFC scores. The baseline occipital and basal ganglia lactate levels were elevated in all subjects; there was a trend toward lower lactate/creatine ratios during riluzole treatment in the basal ganglia spectra but not in occipital cortex spectra. Additional clinical studies of riluzole for both symptomatic and neuroprotective benefit in Huntington's disease are warranted.

Url:

https://api.istex.fr/document/7A70222DCD70873629959102D42BFCB7987DC0C0/fulltext/pdf

DOI: 10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole therapy in Huntington's disease (HD)</title>
<author><name sortKey="Rosas, H Diana" sort="Rosas, H Diana" uniqKey="Rosas H" first="H. Diana" last="Rosas">H. Diana Rosas</name>
</author>
<author><name sortKey="Koroshetz, Walter J" sort="Koroshetz, Walter J" uniqKey="Koroshetz W" first="Walter J." last="Koroshetz">Walter J. Koroshetz</name>
</author>
<author><name sortKey="Jenkins, Bruce G" sort="Jenkins, Bruce G" uniqKey="Jenkins B" first="Bruce G." last="Jenkins">Bruce G. Jenkins</name>
</author>
<author><name sortKey="Chen, Y Iris" sort="Chen, Y Iris" uniqKey="Chen Y" first="Y. Iris" last="Chen">Y. Iris Chen</name>
</author>
<author><name sortKey="Hayden, Douglas L" sort="Hayden, Douglas L" uniqKey="Hayden D" first="Douglas L." last="Hayden">Douglas L. Hayden</name>
</author>
<author><name sortKey="Beal, M Flint" sort="Beal, M Flint" uniqKey="Beal M" first="M. Flint" last="Beal">M. Flint Beal</name>
</author>
<author><name sortKey="Cudkowicz, Merit E" sort="Cudkowicz, Merit E" uniqKey="Cudkowicz M" first="Merit E." last="Cudkowicz">Merit E. Cudkowicz</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q</idno>
<idno type="url">https://api.istex.fr/document/7A70222DCD70873629959102D42BFCB7987DC0C0/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001F81</idno>
<idno type="wicri:Area/Istex/Curation">001F81</idno>
<idno type="wicri:Area/Istex/Checkpoint">003417</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Rosas H:riluzole:therapy:in</idno>
<idno type="wicri:Area/Main/Merge">007949</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:99-0186971</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002E32</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003992</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002D29</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Rosas H:riluzole:therapy:in</idno>
<idno type="wicri:Area/Main/Merge">007B78</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10091628</idno>
<idno type="wicri:Area/PubMed/Corpus">004233</idno>
<idno type="wicri:Area/PubMed/Curation">004233</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004115</idno>
<idno type="wicri:Area/Ncbi/Merge">000018</idno>
<idno type="wicri:Area/Ncbi/Curation">000018</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000018</idno>
<idno type="wicri:doubleKey">0885-3185:1999:Rosas H:riluzole:therapy:in</idno>
<idno type="wicri:Area/Main/Merge">007722</idno>
<idno type="wicri:Area/Main/Curation">004C50</idno>
<idno type="wicri:Area/Main/Exploration">004C50</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Riluzole therapy in Huntington's disease (HD)</title>
<author><name sortKey="Rosas, H Diana" sort="Rosas, H Diana" uniqKey="Rosas H" first="H. Diana" last="Rosas">H. Diana Rosas</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
<affiliation><wicri:noCountry code="subField">Massachusetts;</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Koroshetz, Walter J" sort="Koroshetz, Walter J" uniqKey="Koroshetz W" first="Walter J." last="Koroshetz">Walter J. Koroshetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Jenkins, Bruce G" sort="Jenkins, Bruce G" uniqKey="Jenkins B" first="Bruce G." last="Jenkins">Bruce G. Jenkins</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Chen, Y Iris" sort="Chen, Y Iris" uniqKey="Chen Y" first="Y. Iris" last="Chen">Y. Iris Chen</name>
<affiliation><wicri:noCountry code="subField">Massachusetts;</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Hayden, Douglas L" sort="Hayden, Douglas L" uniqKey="Hayden D" first="Douglas L." last="Hayden">Douglas L. Hayden</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>General Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
<placeName><region type="state">Massachusetts</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beal, M Flint" sort="Beal, M Flint" uniqKey="Beal M" first="M. Flint" last="Beal">M. Flint Beal</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Cudkowicz, Merit E" sort="Cudkowicz, Merit E" uniqKey="Cudkowicz M" first="Merit E." last="Cudkowicz">Merit E. Cudkowicz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Massachusetts</region>
</placeName>
<wicri:cityArea>Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1999-03">1999-03</date>
<biblScope unit="vol">14</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="326">326</biblScope>
<biblScope unit="page" to="330">330</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">7A70222DCD70873629959102D42BFCB7987DC0C0</idno>
<idno type="DOI">10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q</idno>
<idno type="ArticleID">MDS1019</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antagonist</term>
<term>Basal Ganglia (drug effects)</term>
<term>Basal Ganglia (metabolism)</term>
<term>Benzothiazole</term>
<term>Brain (vertebrata)</term>
<term>Chemotherapy</term>
<term>Chorea</term>
<term>Chorea (drug therapy)</term>
<term>Energy metabolism</term>
<term>Excitatory Amino Acid Antagonists (adverse effects)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Female</term>
<term>Glutamate receptor</term>
<term>Human</term>
<term>Humans</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington Disease (metabolism)</term>
<term>Huntington disease</term>
<term>Huntington's disease</term>
<term>Lactate</term>
<term>Lactic Acid (metabolism)</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Magnetic resonance spectroscopy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>NMR spectrometry</term>
<term>Neuroprotective Agents (adverse effects)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Occipital Lobe (drug effects)</term>
<term>Occipital Lobe (metabolism)</term>
<term>Pilot Projects</term>
<term>Psychotropic</term>
<term>Riluzole</term>
<term>Riluzole (adverse effects)</term>
<term>Riluzole (therapeutic use)</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Neuroprotective Agents</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term>
<term>Occipital Lobe</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Chorea</term>
<term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term>
<term>Huntington Disease</term>
<term>Lactic Acid</term>
<term>Occipital Lobe</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Neuroprotective Agents</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Magnetic Resonance Spectroscopy</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Pilot Projects</term>
<term>Severity of Illness Index</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term>
<term>Benzothiazole</term>
<term>Chimiothérapie</term>
<term>Chorée Huntington</term>
<term>Encéphale</term>
<term>Homme</term>
<term>Psychotrope</term>
<term>Riluzole</term>
<term>Récepteur glutamate</term>
<term>Spectrométrie RMN</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We conducted a 6‐week open‐label trial of riluzole (50 mg twice a day) in eight subjects with Huntington's disease. Subjects were evaluated before riluzole treatment, on treatment, and off treatment with the chorea, dystonia, and total functional capacity (TFC) scores from the Unified Huntington's Disease Rating Scale and magnetic resonance spectroscopy measurements of occipital cortex and basal ganglia lactate levels. Adverse events and safety blood and urine tests were assessed throughout the study. All subjects completed the study and riluzole was well tolerated. The age was 45 ± 10.2 years (mean ± standard deviation) and the disease duration was 6.1 ± 4.1 years. The chorea rating score improved by 35% on treatment (p = 0.013) and worsened after discontinuation of treatment (p = 0.026). There were no significant treatment effects on the dystonia or TFC scores. The baseline occipital and basal ganglia lactate levels were elevated in all subjects; there was a trend toward lower lactate/creatine ratios during riluzole treatment in the basal ganglia spectra but not in occipital cortex spectra. Additional clinical studies of riluzole for both symptomatic and neuroprotective benefit in Huntington's disease are warranted.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Massachusetts</li>
</region>
</list>
<tree><noCountry><name sortKey="Chen, Y Iris" sort="Chen, Y Iris" uniqKey="Chen Y" first="Y. Iris" last="Chen">Y. Iris Chen</name>
</noCountry>
<country name="États-Unis"><region name="Massachusetts"><name sortKey="Rosas, H Diana" sort="Rosas, H Diana" uniqKey="Rosas H" first="H. Diana" last="Rosas">H. Diana Rosas</name>
</region>
<name sortKey="Beal, M Flint" sort="Beal, M Flint" uniqKey="Beal M" first="M. Flint" last="Beal">M. Flint Beal</name>
<name sortKey="Cudkowicz, Merit E" sort="Cudkowicz, Merit E" uniqKey="Cudkowicz M" first="Merit E." last="Cudkowicz">Merit E. Cudkowicz</name>
<name sortKey="Hayden, Douglas L" sort="Hayden, Douglas L" uniqKey="Hayden D" first="Douglas L." last="Hayden">Douglas L. Hayden</name>
<name sortKey="Jenkins, Bruce G" sort="Jenkins, Bruce G" uniqKey="Jenkins B" first="Bruce G." last="Jenkins">Bruce G. Jenkins</name>
<name sortKey="Koroshetz, Walter J" sort="Koroshetz, Walter J" uniqKey="Koroshetz W" first="Walter J." last="Koroshetz">Walter J. Koroshetz</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004C50 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004C50 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:7A70222DCD70873629959102D42BFCB7987DC0C0
   |texte=   Riluzole therapy in Huntington's disease (HD)
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Riluzole therapy in Huntington's disease (HD)

Riluzole therapy in Huntington's disease (HD)

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.